INTRODUCTION AND OBJECTIVES: We previously reported that high MET and matriptase expression in RCC cells in bone metastasis indicates their importance in bone metastasis (Mukai et al. Hum Cell, 2015). MET is a high-affinity receptor tyrosine kinase of hepatocyte growth factor (HGF). HGF is secreted as an inactive singlechain precursor, which requires proteolytic activation for conversion to an active form. Matriptase is the most efficient known cellular activator of pro-HGF. Furthermore, activation of matriptase is regulated by HGF activator inhibitor (HAI). In this study, we employed a previously reported mouse model of bone metastasis (Strube et al. Clin Exp Metastasis, 2010) to clarify the significance of the matriptase-induced HGF/MET signaling axis in RCC bone metastasis.
INTRODUCTION AND OBJECTIVES: Bone metastasis has a great impact on the prognosis and clinical morbidity of patients with renal cell carcinoma (RCC) . Overexpression of the Calcium-sensing receptor (CaSR) has been associated with the development of bone metastasis in several tumor entities. The goal of our study was to evaluate the impact of the CaSR in the development of bone metastasis in renal cancer.
METHODS:
The human clear cell RCC line 786-O was stably transfected with the CaSR gene. Cell adhesion to endothelial cells and the extracellular matrix compounds fibronectin, collagen I and IV and a BSA control was determined after calcium treatment of the cells. Chemotactical cell migration was assessed using a Boyden migration chamber with calcium as chemotaxin. Cell proliferation after calcium treatment was quantified via BrdU incorporation. Signalling pathway activation after calcium treatment of the CaSR overexpressing cells was determined by a human phospho-kinase array and Western blot. Development of bone metastasis was evaluated in vivo by an intracardiac injection mouse model. RESULTS: Calcium treated overexpressing CaSR 768-O cells show an increased adhesion to endothelial cells and the extracellular matrix components fibronectin and collagen I, but not to collagen IV. The chemotactical cell migration and proliferation was also induced by calcium treatment. The signalling mediators SHC, AKT, ERK, p38a JNK, p90RSK, CREB were enhanced, SRC reduced active after calcium treatment of CaSR overexpressing cells, but not of control cells. These effects were abolished by the CaSR inhibitor NPS2143. Intracardiac injection of CaSR overexpressing 768-O cells showed an increased rate of bone metastasis in vivo compared to control cells detected by MRI and bioluminescence.
CONCLUSIONS: CaSR is an important component in the mechanism of bone metastasis in RCC in vitro and in vivo. Therefore, targeting CaSR may be beneficial in patients with advanced RCC with high CaSR expression.
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INTRODUCTION AND OBJECTIVES: The presence of androgen receptor (AR) in renal cell carcinoma (RCC) has been shown to be associated with higher tumor stage irrespective of gender. Our previous data have also demonstrated that anti-androgen therapy results in tumor suppression in a xenograft model of AR-positive RCC. Therefore, we hypothesize that intratumoral steroidogenesis is a source of androgens in AR-positive RCC.
METHODS: Using enzyme-linked immunosorbent assay (ELISA), testosterone (T) and dihydrotesterone (DHT) levels were measured in AR-positive human RCC cell lines and human female RCC tissues. Nude mice were also injected with an AR-positive RCC cell line, Caki2. When tumors became palpable, surgical castration was performed and anti-androgen therapies with enzalutamide and abiraterone acetate were initiated. ELISA was then used to measure serum and intratumoral androgen levels. Real-time polymerase chain reaction (RT-PCR) was used to measure the expression levels of key enzymes required for steroidogenesis in RCC cell lines, human RCC tissues, and xenografts.
RESULTS: AR-positive human RCC cell lines and tissues were found to have elevated levels of androgens compared to AR-negative controls (p<0.05), and both expressed key enzymes required for intracellular steroidogenesis. Intratumoral androgen concentrations also remained high following castration even with significant reduction in the serum levels of androgen in a xenograft model. Significant reduction of intratumoral androgen levels was also seen with androgen synthesis inhibitor (p<0.05). Moreover, increased expressions of key enzymes were seen following castration in the xenografts.
CONCLUSIONS: Intracrine androgen biosynthesis is a potential source of androgen in AR-positive RCC, and the androgen signaling axis is a potential target of intervention in AR-positive RCC.
e792
THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 
